Epiminder Limited (EPI) Fair Value & Analysis
Healthcare · AU · Market cap A$74.8K
Fair value as of: Jul 13, 2026
From 1 valuation models · updated yesterday
Fair value updated Jul 13, 2026 — revised from A$1,487 to A$0.4170 (−100.0%) since Jun 24, 2026. Share price −6.8% over the past month.
Price vs Fair Value (7 months)
7‑month range A$0.3150 – A$1.31 · fair‑value band A$0.2752 – A$0.5213 · the A$0.3450 price screens below the A$0.4170 fair value. As of Jul 13, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Epiminder Limited (EPI) currently trades at A$0.3450, while our model-based Fair Value estimate is A$0.4170 — implying the stock looks roughly 20.9% undervalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at A$648K. Revenue grew 89.8% year over year. Fundamentals as of Jul 13, 2026
Our scenario range runs from A$0.2752 (bear case) to A$0.5213 (bull case); at A$0.3450, the current price sits within that range. The share trades about 77% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -45% fair-value upside — at 21%, EPI screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 13, 2026. TTM = trailing twelve months.
About the company
Epiminder Limited develops and manufactures a monitoring device to improve treatment of patients suffering with epileptic seizures and related conditions. It offers Minder system, an implantable sub scalp electroencephalography (EEG) monitoring system which is designed for continuous monitoring of brain activity. The company's Minder system comprises Minder implant, a sub scalp electrode with multiple recording points which enables capture of EEG continuously for months or years; Minder wearable, which receives and stores EEG recordings wirelessly transmitted from the Minder implant to the Minder app; Minder app that collects and transmits EEG data from the Minder implant via Bluetooth and uploads to the Minder cloud for processing; and Minder cloud, a secure, online portal which allows healthcare professionals to download patient data. Epi-Minder Pty Ltd was incorporated in 2017 and is based in Melbourne, Australia.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
Epiminder Limited reported revenue of A$445K in FY2025 versus A$5.5M in FY2023, a compound −71.5%/yr. Reported net income was −A$31.8M in FY2025.
Is EPI fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €73.48 | €59.51 | -19% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $72.59 | $39.33 | -46% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Epiminder Limited (EPI) undervalued?
What is the fair value of EPI?
What is the quality score of EPI?
What is the revenue of Epiminder Limited (EPI)?
What is the net profit margin of EPI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Epiminder Limited analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.